At the 2024 BIO International Convention, Brandon Capital, a leading life sciences venture capital firm in Australasia, revealed the initial success of their sixth fund.
Dr. Chris Nave, co-founder and managing partner, announced a A$270 million first close for the fund and ongoing discussions with additional investors. Fund VI will allow Brandon Capital to continue seeding new life sciences startups in Australia and New Zealand while propelling their international expansion, particularly in the UK, Europe, and the US.
Since its founding in 2007, Brandon Capital has secured over A$1 billion across five funds, supporting more than 60 new ventures in therapeutics, medical devices, and healthtech. As a prominent local life sciences specialist, Brandon Capital provides Australian superannuation funds a chance to diversify their portfolios and gain exposure to a sector with the potential for strong returns, social impact, and improved patient well-being.
”We deeply appreciate our LPs’ continued trust in Brandon Capital and their ongoing recognition that the Life Sciences sector is an exciting and rewarding venture capital asset class. As stewards of this capital, it is a privilege to invest in companies with the capacity to deliver both financial and health returns,” said Dr Chris Nave, Managing Partner of Brandon Capital.
Highlighting Australia’s strength in medical research, Dr. Nave emphasized Brandon Capital’s role in supporting the translation of scientific discoveries into companies developing new treatments, vaccines, and medical devices.
“Australia ranks among the top 10 countries globally for the quality and output of its medical and clinical research. At Brandon, we partner with Australia’s brightest medical minds to support the translation of biomedical discoveries into companies developing new drugs, vaccines and medical devices,” he added. The global biotech sector, valued at approximately US$1.55 trillion, continues to grow unabated, spurred on by events like COVID and the emergence of new therapies. We plan to provide our investors with exposure to this growth. Brandon Capital has had a really productive few years with positive late-stage clinical trial results across a suite of our portfolio companies.”
The firm leverages its offices in these regions, along with the Brandon BioCatalyst network, to source deals and support company growth. Brandon BioCatalyst, a collaborative effort of over 50 Australian and New Zealand medical research institutes and hospitals, focuses on nurturing promising biomedical innovations in the region.
Headquartered in Melbourne, Brandon Capital capitalizes on Australia’s strengths in biotech, including its top-tier medical research and advanced clinical trial infrastructure.
Keep up to date with our stories on LinkedIn, Twitter, Facebook and Instagram.
Australian Life Sciences Venture Capital Firm Brandon Capital announces A$270 million Fund VI first close at 2024 BIO International Convention News Dynamic Business
